Accounts29 Jun 2021 23:56
Included today - "There are a number of other exciting and potentially large new business development opportunities that could drive major increases in covid 19 sales during the remainder of 2021."
Could he mean the antibody test scheduled 3rd quarter for use with boosters ? with AZN stormchaser ? other theraputics we know nada about. Something else entirely we are not aware of ?
The intraday price I can live with , would obviously prefer it to be substantially higher, but believe patience is key and we will get there.
Been looking at other Saliva tests on the market and very few and can't find any home use.
Looked at Rapid response pen proff use only , Deans pharmacy and Newgene proff only ( Chinese)
Looking at income for fit to fly , the new LFTs , Bau , Winterplex usage? SNPsig etc , I think G.M has deliberately set a low bar so that when he reports figures next they exceed market expectations , perhaps this has been a learning curve for him too and moving forwards he has a much more experienced board , a totally diff position to early 2020. Understand frustration totally but still believe that this has huge upside potential from here.
We have all discussed the DHSC dispute to within an inch of our lives and quite frankly are none the wiser. If G.M states they believe they can recoup the money and has set aside 20MM for replacement goods then I will await the outcome, obviously balancing the potential downside against their future earning capacity. Each to their own decision but I think the short time frame in which they have developed a sputum LFT is an amazing achievement and like many await details of CT / partner / production numbers, just another example of the anazing speed with which Nova can react to market demand . Just my thoughts. GLA K